magnesium,5-bromo-2H-pyridin-2-ide,chloride | 376631-32-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: magnesium,5-bromo-2H-pyridin-2-ide,chloride
• CAS: 376631-32-2
• 化学式: C₅H₃BrClMgN
• 分子量: 216.748
• InChiKey: OKOUDSAHHIYZRC-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.33
• 重原子数：
  9.0
• 可旋转键数：
  1.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.89
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  magnesium,5-bromo-2H-pyridin-2-ide,chloride 、 N,N-二甲基-4-甲基苯甲酰胺 以 四氢呋喃 为溶剂， 反应 1.0h， 以4.3 g的产率得到2-(p-toluoyl)-5-bromopyridine
  参考文献：
  名称：

  Preferential Reactivity of Pyridylmagnesiumchloride with N,N-Dialkyl Arylamides over Carbonitriles: Synthesis of 2-(Aroyl) Pyridines

  摘要：

  Reaction of 2-pyridylmagnesium chlorides with N,N-dialkyl arylamides afford exclusively 2-(aroyl) pyridines in high yields and purity without the formation of any tertiary alcohol. This method employs easily available raw materials and avoids the use of hazardous lithium reagents and cryogenic conditions. Further, preferential reactivity of this Grignard reagent with N,N-dialkyl arylamides over its carbonitrile counterparts offers a variety of 2-(aroyl) pyridines including the ones containing carbonitrile groups on the aryl ring.

  DOI：

  10.1080/00397910802594284
• 作为产物：
  描述：

  5-溴-2-碘吡啶 、 异丙基氯化镁 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 magnesium,5-bromo-2H-pyridin-2-ide,chloride
  参考文献：
  名称：

  Preferential Reactivity of Pyridylmagnesiumchloride with N,N-Dialkyl Arylamides over Carbonitriles: Synthesis of 2-(Aroyl) Pyridines

  摘要：

  Reaction of 2-pyridylmagnesium chlorides with N,N-dialkyl arylamides afford exclusively 2-(aroyl) pyridines in high yields and purity without the formation of any tertiary alcohol. This method employs easily available raw materials and avoids the use of hazardous lithium reagents and cryogenic conditions. Further, preferential reactivity of this Grignard reagent with N,N-dialkyl arylamides over its carbonitrile counterparts offers a variety of 2-(aroyl) pyridines including the ones containing carbonitrile groups on the aryl ring.

  DOI：

  10.1080/00397910802594284

文献信息

• Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20180037594A1

  公开（公告）日：2018-02-08

  The present invention relates to compounds of general formula I, wherein the groups R 1 , R 2 and n are defined as in claim 1 , which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.

  本发明涉及通式I的化合物，其中基团R1、R2和n的定义如权利要求书中所述，该化合物具有有价值的药理学特性，特别是结合到生长激素释放激素酰基转移酶（GOAT）并调节其活性。这些化合物适用于治疗和预防可能受该受体影响的疾病，如代谢性疾病，特别是肥胖症。
• Synthesis of heteroarylamine intermediate compounds
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20030135046A1

  公开（公告）日：2003-07-17

  Disclosed are novel 2-(5-halopyridyl) and 2-(5-halopyrimidinyl) magnesium halides, processes of making and their use in the efficient synthesis in their respective 5-halo-2-substituted pyridines and pyrimidines.

  揭示了新颖的2-(5-卤代吡啶基)和2-(5-卤代嘧啶基)镁卤化物，以及制备过程以及它们在各自的5-卤代-2-取代吡啶和嘧啶的高效合成中的用途。
• Novel synthesis of heteroarylamine intermediate compounds
  申请人：——

  公开号：US20020045754A1

  公开（公告）日：2002-04-18

  Disclosed are novel 2-(5-halopyridyl) and 2-(5-halopyrimidinyl) magnesium halides, processes of making and their use in the efficient synthesis in their respective 5-halo-2-substituted pyridines and pyrimidines.

  本发明涉及新型的2-(5-卤代吡啶基)和2-(5-卤代嘧啶基)镁卤化物，其制备过程以及它们在各自的5-卤代-2-取代吡啶和嘧啶的高效合成中的应用。
• Pyridine intermediate compound
  申请人：——

  公开号：US20020049333A1

  公开（公告）日：2002-04-25

  Disclosed are novel 2-(5-halopyridyl) and 2-(5-halopyrimidinyl) magnesium halides, processes of making and their use in the efficient synthesis in their respective 5-halo-2- substituted pyridines and pyrimidines.

  本发明涉及新型的2-(5-卤代吡啶基)和2-(5-卤代嘧啶基)镁卤化物，其制备工艺及其在有效合成相应的5-卤代2-取代吡啶和嘧啶中的应用。
• Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10308667B2

  公开（公告）日：2019-06-04

  The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.

  本发明涉及通式 I 的化合物、 其中基团 R1、R2 和 n 的定义如权利要求 1 所述，这些化合物具有重要的药理特性，特别是能与胃泌素 O-酰基转移酶（GOAT）结合并调节其活性。这些化合物适用于治疗和预防受该受体影响的疾病，如代谢性疾病，特别是肥胖症。